Chromocell Therapeutics Corp
For the period ended Mar 31, 2024. Filed May 15, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 15, 2024
PTHS$8.90-5.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Cash Flows
**FOR THE THREE MONTHS ENDED MARCH 31, 2024 AND 2023
| For the Three Months Ended | For the Three Months Ended | |
|---|---|---|
| March 31, 2024 | March 31, 2023 | |
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||
| Net loss | $(2,562,330) | $(966,561) |
| Adjustments to reconcile net loss to net cash used in operating activities | ||
| Amortization of debt discount | 605,630 | 31,650 |
| Stock-based compensation | 292,552 | 272,221 |
| Changes in operating assets and liabilities: | ||
| Accounts payable and accrued expenses | 90,994 | 367,326 |
| Accrued compensation | (152,023) | 121,995 |
| Due from Chromocell Corporation | (45,786) | — |
| Prepaid | (220,930) | — |
| Net Cash Used In Operating Activities | (1,991,893) | (173,369) |
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||
| Proceeds from loan payable - related party, net of debt discount | — | 166,903 |
| Payment of bridge loan, net of debt discount | (214,757) | — |
| Common stock issued for cash | 5,972,000 | — |
| Recission of common stock | (91,512) | — |
| Net Cash Provided By Financing Activities | 5,665,731 | 166,903 |
| NET INCREASE (DECREASE) IN CASH | 3,673,838 | (6,466) |
| CASH AT BEGINNING OF PERIOD | 96,391 | 55,074 |
| CASH AT END OF PERIOD | $3,770,229 | $48,608 |
| Supplemental cash flow information: | ||
| Cash paid for income taxes | $— | $— |
| Cash paid for interest expense | $— | $— |
| NONCASH INVESTING AND FINANCING ACTIVITIES: | ||
| Debt discount from common stock issued for extension of bridge loan | $447,779 | $— |
| Conversion of notes | $1,362,821 | $— |
| Transfer of liabilities to Chromocell Corp for Preferred Stock | $2,153,362 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.